Pressure BioSciences (OTCQB:PBIO) has been generating some buzz as of late, recently featured in two different investment articles listing stocks to watch in the life sciences space.
The company, which is focused on developing its pressure cycling technology (PCT), says its CEO Richard T. Schumacher will be presenting a corporate overview and business update at the second annual Marcum MicroCap Conference on Thursday May 30, at 4pm ET.
The conference, being held at the Grand Hyatt Hotel in New York City, is expected to draw more than 1,000 institutional investors, sell-side analysts and investment bankers.
Earlier this month, the company's shares rallied after it said that researchers at Harvard Medical School published a scientific paper describing a non-invasive method that could potentially screen for multiple diseases by gaining information about the gastrointestinal (GI) system, using PCT and certain chemicals.
The method, a description of which was published in the journal Analytical Chemistry by a team of scientists led by Dr. Bruce Kristal, Associate Professor of Surgery at Harvard Medical School, uses the company's technology and certain chemicals to extract intact lipids from fecal material.
The idea is to get as much information as possible about what is happening in the GI system, known as the gut, and its role in health and disease in certain high-risk populations. This could include premature infants, newborns, and the elderly.
Pressure BioSciences is focused on the development, marketing, and sale of proprietary laboratory instrumentation and associated consumables based on PCT, which has several applications in the estimated $6 billion life sciences sample preparation market.
In the study that was cited in the announcement of the method for the improved extraction of lipids from fecal matter, the authors said that the new method "opens the door to the use of fecal lipid profiling for both scientific and clinical applications" and that it "provides a reproducible, generally applicable, broad-based, and non-invasive technique for establishing gut function in patients regardless of age or disease."
Other applications for PCT include mass spectrometry, bio-therapeutics characterization, vaccine development, soil and plant biology, forensics, histology, and counter-bioterror applications.
The company is featured in Investing.com article titled "Three Diagnostic Stocks with Oomph", and The Motley Fool article titled "Life Sciences Space Gets A New Look Following Big Merger".
In the Investing.com article, Pressure BioSciences is likened to Exact Sciences (NASDAQ:EXAS) given the company's breakthrough announcement on May 16. "This has the potential of opening up this process to diagnose a wide range of gut conditions and provide valuable information to doctor’s about a patient’s condition," the Investing.com contributor wrote.
"On the back of one test, EXAS has been able to garner a $700 million market cap on the open market so there is some potential here for PBIO if it is able to build upon its recent study results," the writer concluded.
Also in May, Pressure BioSciences reported a 21 per cent increase year-over-year in revenue with PCT products, and said it expects to release several new products in 2013. Shares of the company are up 80 per cent since the start of the year.
The Investing.com and Motley Fool articles can be found at the links below.
No comments:
Post a Comment